
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc, a clinical-stage biotechnology company, has shown potential for significant growth with its pipeline candidates advancing in high-value indications, particularly with SER-252. The company's POZ Platform delivery technology enhances the effectiveness of drug candidates and positions Serina favorably in the competitive landscape, creating opportunities for substantial market penetration. Additionally, the anticipated clinical success of SER-270 and its subsequent potential contributions to company valuations could offer long-term upside, further solidifying the positive outlook for Serina's stock.
Bears say
Serina Therapeutics reported a net loss of $0.64 per share, signaling significant financial difficulties within the company as it progresses through clinical development stages. The company faces numerous risks, including the potential inability to advance its lead product candidate, SER-252, into clinical trials and secure regulatory approval, along with challenges related to competition and market dynamics that could hinder commercial uptake. Additionally, projections for a deeper net loss of $2.01 per share in the full-year 2025 compared to an original estimate of $0.36 indicate worsening financial health and raise concerns about possible near- to medium-term dilution risks.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares